It's about time - directing our attention toward modifying the course of COPD

Mario Cazzola, Nicola A. Hanania, Paul W. Jones, Donald A. Mahler, Barry Make, Jill Ohar, Stephen Rennard

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The course of COPD has traditionally been equated with an accelerated decline in the forced expiratory volume in one second (FEVi) over time in patients with COPD, compared to healthy individuals. However, other important clinical outcomes associated with COPD also worsen over time and should also be considered in conceptualizing the course of COPD. These include health status, breathlessness related to activities of daily living, exercise capacity, the frequency of exacerbations, and peripheral muscle weakness. These outcomes are often quite responsive to therapy of COPD. Presently there is no evidence that any treatment other than smoking cessation can normalise the rate of decline of FEVi, and therefore be considered as modifying the physiologic course of the disease. Thus, smoking cessation reigns as the primary disease modifying strategy in COPD. Even though there are a number of smoking cessation products on the market and smoking prevalence continues to decrease marginally each year, more needs to be done to provide comprehensive programmes to help people quit smoking. In the US in 2004, 37.5% of preventable deaths were found to be tobacco-related. The FEVi does not reflect the clinical manifestations or the total burden of this multidimensional illness. As novel therapeutic agents become available that may alter the underlying pathology of COPD, additional markers and outcomes of disease progression will be needed to provide a more comprehensive assessment. There has been increasing interest in predicting and assessing mortality as it is the final outcome of disease progression. In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)S37-S48
JournalRespiratory Medicine
Volume102
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 1 2008

Fingerprint

Chronic Obstructive Pulmonary Disease
Smoking Cessation
Disease Progression
Smoking
Tobacco Use Cessation Products
Cost of Illness
Muscle Weakness
Forced Expiratory Volume
Activities of Daily Living
Dyspnea
Health Status
Tobacco
Therapeutics
Exercise
Pathology
Drug Therapy
Lung
Mortality

Keywords

  • Bronchodilators
  • Chronic obstructive
  • Formoterol
  • Inhaled
  • Outcomes
  • Salmeterol
  • Smoking cessation
  • Therapy
  • Tiotropium
  • corticosteroids
  • pulmonary disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Cazzola, M., Hanania, N. A., Jones, P. W., Mahler, D. A., Make, B., Ohar, J., & Rennard, S. (2008). It's about time - directing our attention toward modifying the course of COPD. Respiratory Medicine, 102(SUPPL. 1), S37-S48. https://doi.org/10.1016/S0954-6111(08)70006-4

It's about time - directing our attention toward modifying the course of COPD. / Cazzola, Mario; Hanania, Nicola A.; Jones, Paul W.; Mahler, Donald A.; Make, Barry; Ohar, Jill; Rennard, Stephen.

In: Respiratory Medicine, Vol. 102, No. SUPPL. 1, 01.06.2008, p. S37-S48.

Research output: Contribution to journalArticle

Cazzola, M, Hanania, NA, Jones, PW, Mahler, DA, Make, B, Ohar, J & Rennard, S 2008, 'It's about time - directing our attention toward modifying the course of COPD', Respiratory Medicine, vol. 102, no. SUPPL. 1, pp. S37-S48. https://doi.org/10.1016/S0954-6111(08)70006-4
Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J et al. It's about time - directing our attention toward modifying the course of COPD. Respiratory Medicine. 2008 Jun 1;102(SUPPL. 1):S37-S48. https://doi.org/10.1016/S0954-6111(08)70006-4
Cazzola, Mario ; Hanania, Nicola A. ; Jones, Paul W. ; Mahler, Donald A. ; Make, Barry ; Ohar, Jill ; Rennard, Stephen. / It's about time - directing our attention toward modifying the course of COPD. In: Respiratory Medicine. 2008 ; Vol. 102, No. SUPPL. 1. pp. S37-S48.
@article{1dc82f3e592c470da62e5823185bbde0,
title = "It's about time - directing our attention toward modifying the course of COPD",
abstract = "The course of COPD has traditionally been equated with an accelerated decline in the forced expiratory volume in one second (FEVi) over time in patients with COPD, compared to healthy individuals. However, other important clinical outcomes associated with COPD also worsen over time and should also be considered in conceptualizing the course of COPD. These include health status, breathlessness related to activities of daily living, exercise capacity, the frequency of exacerbations, and peripheral muscle weakness. These outcomes are often quite responsive to therapy of COPD. Presently there is no evidence that any treatment other than smoking cessation can normalise the rate of decline of FEVi, and therefore be considered as modifying the physiologic course of the disease. Thus, smoking cessation reigns as the primary disease modifying strategy in COPD. Even though there are a number of smoking cessation products on the market and smoking prevalence continues to decrease marginally each year, more needs to be done to provide comprehensive programmes to help people quit smoking. In the US in 2004, 37.5{\%} of preventable deaths were found to be tobacco-related. The FEVi does not reflect the clinical manifestations or the total burden of this multidimensional illness. As novel therapeutic agents become available that may alter the underlying pathology of COPD, additional markers and outcomes of disease progression will be needed to provide a more comprehensive assessment. There has been increasing interest in predicting and assessing mortality as it is the final outcome of disease progression. In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy.",
keywords = "Bronchodilators, Chronic obstructive, Formoterol, Inhaled, Outcomes, Salmeterol, Smoking cessation, Therapy, Tiotropium, corticosteroids, pulmonary disease",
author = "Mario Cazzola and Hanania, {Nicola A.} and Jones, {Paul W.} and Mahler, {Donald A.} and Barry Make and Jill Ohar and Stephen Rennard",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/S0954-6111(08)70006-4",
language = "English (US)",
volume = "102",
pages = "S37--S48",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - It's about time - directing our attention toward modifying the course of COPD

AU - Cazzola, Mario

AU - Hanania, Nicola A.

AU - Jones, Paul W.

AU - Mahler, Donald A.

AU - Make, Barry

AU - Ohar, Jill

AU - Rennard, Stephen

PY - 2008/6/1

Y1 - 2008/6/1

N2 - The course of COPD has traditionally been equated with an accelerated decline in the forced expiratory volume in one second (FEVi) over time in patients with COPD, compared to healthy individuals. However, other important clinical outcomes associated with COPD also worsen over time and should also be considered in conceptualizing the course of COPD. These include health status, breathlessness related to activities of daily living, exercise capacity, the frequency of exacerbations, and peripheral muscle weakness. These outcomes are often quite responsive to therapy of COPD. Presently there is no evidence that any treatment other than smoking cessation can normalise the rate of decline of FEVi, and therefore be considered as modifying the physiologic course of the disease. Thus, smoking cessation reigns as the primary disease modifying strategy in COPD. Even though there are a number of smoking cessation products on the market and smoking prevalence continues to decrease marginally each year, more needs to be done to provide comprehensive programmes to help people quit smoking. In the US in 2004, 37.5% of preventable deaths were found to be tobacco-related. The FEVi does not reflect the clinical manifestations or the total burden of this multidimensional illness. As novel therapeutic agents become available that may alter the underlying pathology of COPD, additional markers and outcomes of disease progression will be needed to provide a more comprehensive assessment. There has been increasing interest in predicting and assessing mortality as it is the final outcome of disease progression. In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy.

AB - The course of COPD has traditionally been equated with an accelerated decline in the forced expiratory volume in one second (FEVi) over time in patients with COPD, compared to healthy individuals. However, other important clinical outcomes associated with COPD also worsen over time and should also be considered in conceptualizing the course of COPD. These include health status, breathlessness related to activities of daily living, exercise capacity, the frequency of exacerbations, and peripheral muscle weakness. These outcomes are often quite responsive to therapy of COPD. Presently there is no evidence that any treatment other than smoking cessation can normalise the rate of decline of FEVi, and therefore be considered as modifying the physiologic course of the disease. Thus, smoking cessation reigns as the primary disease modifying strategy in COPD. Even though there are a number of smoking cessation products on the market and smoking prevalence continues to decrease marginally each year, more needs to be done to provide comprehensive programmes to help people quit smoking. In the US in 2004, 37.5% of preventable deaths were found to be tobacco-related. The FEVi does not reflect the clinical manifestations or the total burden of this multidimensional illness. As novel therapeutic agents become available that may alter the underlying pathology of COPD, additional markers and outcomes of disease progression will be needed to provide a more comprehensive assessment. There has been increasing interest in predicting and assessing mortality as it is the final outcome of disease progression. In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy.

KW - Bronchodilators

KW - Chronic obstructive

KW - Formoterol

KW - Inhaled

KW - Outcomes

KW - Salmeterol

KW - Smoking cessation

KW - Therapy

KW - Tiotropium

KW - corticosteroids

KW - pulmonary disease

UR - http://www.scopus.com/inward/record.url?scp=45849109959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849109959&partnerID=8YFLogxK

U2 - 10.1016/S0954-6111(08)70006-4

DO - 10.1016/S0954-6111(08)70006-4

M3 - Article

C2 - 18582796

AN - SCOPUS:45849109959

VL - 102

SP - S37-S48

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - SUPPL. 1

ER -